|
|
 Previous Article | Table of Contents | Next Article 
Expression of CD28 and CD40 in human myeloma cells: a comparative study
with normal plasma cells
C Pellat-Deceunynck, R Bataille, N Robillard, JL Harousseau, MJ Rapp, N Juge- Morineau, J Wijdenes and M Amiot
Laboratoire d'Oncogenese Immunohematologique, Institut de Biologie, Nantes,
France.
CD28 and CD40 are important activation pathways for T and B lymphocytes,
respectively. The aim of this study was to determine the phenotype of
plasma cells (PCs) and the expression of these two molecules, CD28 and
CD40. Therefore, we have compared their expression on normal PCs from bone
marrows and tonsils with that of freshly explanted malignant PCs from 31
patients with multiple myeloma (MM) and those from 12 human myeloma cell
lines. For this purpose, we first described a new approach to identify
plasma cells in bone marrow using two-color immunofluorescence analysis
with anti-CD38 and B-B4 antibodies. B-B4 specifically recognizes all PC;
all B-B4 cells are located within the CD38 bright fraction and vice versa.
CD19 and CD56 expression, which was previously shown to discriminate normal
from malignant PCs, was also evaluated. In the current report, we show that
normal PCs express CD19, CD40, and CD56 (weakly as a subset) and lack CD28.
Regardless of whether they express CD19, CD56 is clearly upregulated during
the medullary chronic and accelerated phases of MM, but is absent in
patients with extramedullary involvement. Although the level of CD40
expression is variable, only patients in accelerated phases expressed high
CD40 levels. Finally, whereas CD28 was negative in chronic phase (as in
normal PCs), it was expressed in 63% of the patients in accelerated phases
and 100% of cell lines. Our data strongly suggest that both disease
activity and medullary homing (or not) are correlated with the expression
of CD19, CD40, CD28, and CD56 on human myeloma cells.
Volume 84,
Issue 8,
pp. 2597-2603,
10/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. L. Good, D. T. Avery, and S. G. Tangye
Resting Human Memory B Cells Are Intrinsically Programmed for Enhanced Survival and Responsiveness to Diverse Stimuli Compared to Naive B Cells
J. Immunol.,
January 15, 2009;
182(2):
890 - 901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mateo, M. A. Montalban, M.-B. Vidriales, J. J. Lahuerta, M. V. Mateos, N. Gutierrez, L. Rosinol, L. Montejano, J. Blade, R. Martinez, et al.
Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
J. Clin. Oncol.,
June 1, 2008;
26(16):
2737 - 2744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, et al.
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Haematologica,
March 1, 2008;
93(3):
431 - 438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Menoret, P. Gomez-Bougie, A. Geffroy-Luseau, S. Daniels, P. Moreau, S. Le Gouill, J.-L. Harousseau, R. Bataille, M. Amiot, and C. Pellat-Deceunynck
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells
Blood,
August 15, 2006;
108(4):
1346 - 1352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Tai, X.-F. Li, L. Catley, R. Coffey, I. Breitkreutz, J. Bae, W. Song, K. Podar, T. Hideshima, D. Chauhan, et al.
Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications
Cancer Res.,
December 15, 2005;
65(24):
11712 - 11720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Chen, B. Issa, S. Huang, E. Aston, J. Xu, M. Yu, A. R. Brothman, and M. Glenn
A Practical Approach to the Detection of Prognostically Significant Genomic Aberrations in Multiple Myeloma
J. Mol. Diagn.,
November 1, 2005;
7(5):
560 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Tai, X. Li, X. Tong, D. Santos, T. Otsuki, L. Catley, O. Tournilhac, K. Podar, T. Hideshima, R. Schlossman, et al.
Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma
Cancer Res.,
July 1, 2005;
65(13):
5898 - 5906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mateo, M. Castellanos, A. Rasillo, N. C. Gutierrez, Ma. A. Montalban, Ma. L. Martin, J. Ma. Hernandez, Ma. C. Lopez-Berges, L. Montejano, J. Blade, et al.
Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma
Clin. Cancer Res.,
May 15, 2005;
11(10):
3661 - 3667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Riley and C. H. June
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Blood,
January 1, 2005;
105(1):
13 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Velangi, E. C. Matheson, G. J. Morgan, G. H. Jackson, P. R. Taylor, A. G. Hall, and J. A.E. Irving
DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma
Carcinogenesis,
October 1, 2004;
25(10):
1795 - 1803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Lewis, M. Merched-Sauvage, J. J. Goronzy, C. M. Weyand, and A. N. Vallejo
Tumor Necrosis Factor-{alpha} and CD80 Modulate CD28 Expression through a Similar Mechanism of T-cell Receptor-independent Inhibition of Transcription
J. Biol. Chem.,
July 9, 2004;
279(28):
29130 - 29138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Tai, L. P. Catley, C. S. Mitsiades, R. Burger, K. Podar, R. Shringpaure, T. Hideshima, D. Chauhan, M. Hamasaki, K. Ishitsuka, et al.
Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications
Cancer Res.,
April 15, 2004;
64(8):
2846 - 2852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Bharti, S. Shishodia, J. M. Reuben, D. Weber, R. Alexanian, S. Raj-Vadhan, Z. Estrov, M. Talpaz, and B. B. Aggarwal
Nuclear factor-{kappa}B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
Blood,
April 15, 2004;
103(8):
3175 - 3184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Dotti, B. Savoldo, P. Yotnda, D. Rill, and M. K. Brenner
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40+ and CD40- plasmacytoma cells
Blood,
June 17, 2002;
100(1):
200 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Ely and D. M. Knowles
Expression of CD56/Neural Cell Adhesion Molecule Correlates with the Presence of Lytic Bone Lesions in Multiple Myeloma and Distinguishes Myeloma from Monoclonal Gammopathy of Undetermined Significance and Lymphomas with Plasmacytoid Differentiation
Am. J. Pathol.,
April 1, 2002;
160(4):
1293 - 1299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Tai, K. Podar, D. Gupta, B. Lin, G. Young, M. Akiyama, and K. C. Anderson
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells
Blood,
February 15, 2002;
99(4):
1419 - 1427.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. S. Shapiro, M. N. Mollenauer, and A. Weiss
Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression
Blood,
July 1, 2001;
98(1):
187 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Jego, R. Bataille, and C. Pellat-Deceunynck
Interleukin-6 is a growth factor for nonmalignant human plasmablasts
Blood,
March 15, 2001;
97(6):
1817 - 1822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Tong, M. H. Papayoti, G. Netto, D. T. Armstrong, G. Ordonez, J. M. Lawson, and M. J. Stone
Growth-inhibitory Effects of CD40 Ligand (CD154) and Its Endogenous Expression in Human Breast Cancer
Clin. Cancer Res.,
March 1, 2001;
7(3):
691 - 703.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Barille, R. Bataille, M.-J. Rapp, J.-L. Harousseau, and M. Amiot
Production of Metalloproteinase-7 (Matrilysin) by Human Myeloma Cells and Its Potential Involvement in Metalloproteinase-2 Activation
J. Immunol.,
November 15, 1999;
163(10):
5723 - 5728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Thabard, S. Barille, M. Collette, J.-L. Harousseau, M.-J. Rapp, R. Bataille, and M. Amiot
Myeloma Cells Release Soluble Interleukin-6R{{alpha}} in Relation to Disease Progression by Two Distinct Mechanisms: Alternative Splicing and Proteolytic Cleavage
Clin. Cancer Res.,
October 1, 1999;
5(10):
2693 - 2697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Sahota, R. Garand, R. Mahroof, A. Smith, N. Juge-Morineau, F. K. Stevenson, and R. Bataille
VH Gene Analysis of IgM-Secreting Myeloma Indicates an Origin From a Memory Cell Undergoing Isotype Switch Events
Blood,
August 1, 1999;
94(3):
1070 - 1076.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Jego, N. Robillard, D. Puthier, M. Amiot, F. Accard, D. Pineau, J.-L. Harousseau, R. Bataille, and C. Pellat-Deceunynck
Reactive Plasmacytoses Are Expansions of Plasmablasts Retaining the Capacity to Differentiate Into Plasma Cells
Blood,
July 15, 1999;
94(2):
701 - 712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tarte, X.-G. Zhang, E. Legouffe, C. Hertog, M. Mehtali, J.-F. Rossi, and B. Klein
Induced Expression of B7-1 on Myeloma Cells Following Retroviral Gene Transfer Results in Tumor-Specific Recognition by Cytotoxic T Cells
J. Immunol.,
July 1, 1999;
163(1):
514 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. Vallejo, J. C. Brandes, C. M. Weyand, and J. J. Goronzy
Modulation of CD28 Expression: Distinct Regulatory Pathways During Activation and Replicative Senescence
J. Immunol.,
June 1, 1999;
162(11):
6572 - 6579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Pellat-Deceunynck, G. Jego, J.-L. Harousseau, H. Vie, and R. Bataille
Isolation of Human Lymphocyte Antigens Class I-restricted Cytotoxic T Lymphocytes against Autologous Myeloma Cells
Clin. Cancer Res.,
March 1, 1999;
5(3):
705 - 709.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Garcia-Sanz, A. Orfao, M. Gonzalez, M.D. Tabernero, J. Blade, M.J. Moro, J. Fernandez-Calvo, M.A. Sanz, J.A. Perez-Simon, A. Rasillo, et al.
Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics
Blood,
February 1, 1999;
93(3):
1032 - 1037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Cerutti, H. Zan, A. Schaffer, L. Bergsagel, N. Harindranath, E. E. Max, and P. Casali
CD40 Ligand and Appropriate Cytokines Induce Switching to IgG, IgA, and IgE and Coordinated Germinal Center and Plasmacytoid Phenotypic Differentiation in a Human Monoclonal IgM+IgD+ B Cell Line
J. Immunol.,
March 1, 1998;
160(5):
2145 - 2157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Francisco, S. L. Gawlak, and C. B. Siegall
Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1
J. Biol. Chem.,
September 26, 1997;
272(39):
24165 - 24169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Yi, S. Dabadghao, A. Osterborg, S. Bergenbrant, and G. Holm
Myeloma Bone Marrow Plasma Cells: Evidence for Their Capacity as Antigen-Presenting Cells
Blood,
September 1, 1997;
90(5):
1960 - 1967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Francisco, G. J. Schreiber, C. R. Comereski, L. E. Mezza, G. L. Warner, T. J. Davidson, J. A. Ledbetter, and C. B. Siegall
In Vivo Efficacy and Toxicity of a Single-Chain Immunotoxin Targeted to CD40
Blood,
June 15, 1997;
89(12):
4493 - 4500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
